Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alina Molchadsky is active.

Publication


Featured researches published by Alina Molchadsky.


Nature Genetics | 2012

Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues

Gilad Landan; Netta Mendelson Cohen; Zohar Mukamel; Amir Bar; Alina Molchadsky; Ran Brosh; Shirley Horn-Saban; Daniela Amann Zalcenstein; Naomi Goldfinger; Adi Zundelevich; Einav Nili Gal-Yam; Varda Rotter; Amos Tanay

DNA methylation has been comprehensively profiled in normal and cancer cells, but the dynamics that form, maintain and reprogram differentially methylated regions remain enigmatic. Here, we show that methylation patterns within populations of cells from individual somatic tissues are heterogeneous and polymorphic. Using in vitro evolution of immortalized fibroblasts for over 300 generations, we track the dynamics of polymorphic methylation at regions developing significant differential methylation on average. The data indicate that changes in population-averaged methylation occur through a stochastic process that generates a stream of local and uncorrelated methylation aberrations. Despite the stochastic nature of the process, nearly deterministic epigenetic remodeling emerges on average at loci that lose or gain resistance to methylation accumulation. Changes in the susceptibility to methylation accumulation are correlated with changes in histone modification and CTCF occupancy. Characterizing epigenomic polymorphism within cell populations is therefore critical to understanding methylation dynamics in normal and cancer cells.


PLOS ONE | 2008

p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner.

Alina Molchadsky; Igor Shats; Naomi Goldfinger; Meirav Pevsner-Fischer; Melissa V. Olson; Ariel Rinon; Eldad Tzahor; Guillermina Lozano; Dov Zipori; Rachel Sarig; Varda Rotter

Background The tumor suppressor p53 is an important regulator that controls various cellular networks, including cell differentiation. Interestingly, some studies suggest that p53 facilitates cell differentiation, whereas others claim that it suppresses differentiation. Therefore, it is critical to evaluate whether this inconsistency represents an authentic differential p53 activity manifested in the various differentiation programs. Methodology/Principal Findings To clarify this important issue, we conducted a comparative study of several mesenchymal differentiation programs. The effects of p53 knockdown or enhanced activity were analyzed in mouse and human mesenchymal cells, representing various stages of several differentiation programs. We found that p53 down-regulated the expression of master differentiation-inducing transcription factors, thereby inhibiting osteogenic, adipogenic and smooth muscle differentiation of multiple mesenchymal cell types. In contrast, p53 is essential for skeletal muscle differentiation and osteogenic re-programming of skeletal muscle committed cells. Conclusions These comparative studies suggest that, depending on the specific cell type and the specific differentiation program, p53 may exert a positive or a negative effect, and thus can be referred as a “guardian of differentiation” at large.


Carcinogenesis | 2010

p53 is balancing development, differentiation and de-differentiation to assure cancer prevention.

Alina Molchadsky; Noa Rivlin; Ran Brosh; Varda Rotter; Rachel Sarig

Many of the roles played by the tumor suppressor p53 in restraining cancer initiation and progression are well established. These include the ability of p53 to induce cell-cycle arrest, DNA repair, senescence and apoptosis. In addition, during the 30 years of p53 research, numerous studies have implicated p53 in the regulation of differentiation and developmental pathways. Here, we summarize the data on these relatively less-characterized functions of p53, including its involvement in embryogenesis and various differentiation programs, as well as its function in restraining de-differentiation of mature somatic cells. Besides the well-known functions of p53 as a cell-cycle regulator and a mediator of apoptosis, both coincide with differentiation processes, p53 was shown to exert its effects on various differentiation programs via direct regulation of specific key factors controlling these programs. The complex regulation by p53, which acts to suppress or to induce differentiation, is mainly the result of the specific cell type and fate. We argue that regulation of differentiation is pivotal for the tumor-suppressive activity of p53, which act to maintain the proper cellular state, preventing improper maturation or reprogramming. This conclusion is further supporting the notion that aberrant differentiation is associated with malignant transformation.


Cell Death & Differentiation | 2011

Mutant p53 R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells

Ira Kogan-Sakin; Yuval Tabach; Yossi Buganim; Alina Molchadsky; Hilla Solomon; Shalom Madar; I. Kamer; Perry Stambolsky; A. Shelly; Naomi Goldfinger; S. Valsesia-Wittmann; A. Puisieux; A. Zundelevich; Einav Nili Gal-Yam; C. Avivi; Iris Barshack; M. Brait; D. Sidransky; Eytan Domany; Varda Rotter

A mutation within one allele of the p53 tumor suppressor gene can inactivate the remaining wild-type allele in a dominant-negative manner and in some cases can exert an additional oncogenic activity, known as mutant p53 ‘gain of function’ (GOF). To study the role of p53 mutations in prostate cancer and to discriminate between the dominant-negative effect and the GOF activity of mutant p53, we measured, using microarrays, the expression profiles of three immortalized prostate epithelial cultures expressing wild-type, inactivated p53 or mutated p53. Analysis of these gene expression profiles showed that both inactivated p53 and p53R175H mutant expression resulted in the upregulation of cell cycle progression genes. A second group, which was upregulated exclusively by mutant p53R175H, was predominantly enriched in developmental genes. This group of genes included the Twist1, a regulator of metastasis and epithelial–mesenchymal transition (EMT). Twist1 levels were also elevated in metastatic prostate cancer-derived cell line DU145, in immortalized lung fibroblasts and in a subset of lung cancer samples, all in a mutant p53-dependent manner. p53R175H mutant bearing immortalized epithelial cells showed typical features of EMT, such as higher expression of mesenchymal markers, lower expression of epithelial markers and enhanced invasive properties in vitro. The mechanism by which p53R175H mutant induces Twist1 expression involves alleviation of the epigenetic repression. Our data suggest that Twist1 expression might be upregulated following p53 mutation in cancer cells.


Cell Death & Differentiation | 2013

p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity

Alina Molchadsky; Osnat Ezra; P G Amendola; D Krantz; Ira Kogan-Sakin; Yossi Buganim; Noa Rivlin; Naomi Goldfinger; V Folgiero; R Falcioni; Rachel Sarig; Varda Rotter

Proper regulation of white and brown adipogenic differentiation is important for maintaining an organism’s metabolic profile in a homeostatic state. The recent observations showing that the p53 tumor suppressor plays a role in metabolism raise the question of whether it is involved in the regulation of white and brown adipocyte differentiation. By using several in vitro models, representing various stages of white adipocyte differentiation, we found that p53 exerts a suppressive effect on white adipocyte differentiation in both mouse and human cells. Moreover, our in vivo analysis indicated that p53 is implicated in protection against diet-induced obesity. In striking contrast, our data shows that p53 exerts a positive regulatory effect on brown adipocyte differentiation. Abrogation of p53 function in skeletal muscle committed cells reduced their capacity to differentiate into brown adipocytes and histological analysis of brown adipose tissue revealed an impaired morphology in both embryonic and adult p53-null mice. Thus, depending on the specific adipogenic differentiation program, p53 may exert a positive or a negative effect. This cell type dependent regulation reflects an additional modality of p53 in maintaining a homeostatic state, not only in the cell, but also in the organism at large.


Carcinogenesis | 2009

Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1

Ira Kogan-Sakin; Merav Cohen; Nicole Paland; Shalom Madar; Hilla Solomon; Alina Molchadsky; Ran Brosh; Yosef Buganim; Naomi Goldfinger; Helmut Klocker; Jack A. Schalken; Varda Rotter

It is well accepted that tumor microenvironment is essential for tumor cells survival, cancer progression and metastasis. However, the mechanisms by which tumor cells interact with their surrounding at early stages of cancer development are largely unidentified. The aim of this study was to identify specific molecules involved in stromal-epithelial interactions that might contribute to early stages of prostate tumor formation. Here, we show that conditioned medium (CM) from immortalized non-transformed prostate epithelial cells stimulated immortalized prostate stromal cells to express cancer-related molecules. CM obtained from epithelial cells triggered stromal cells to express and secrete CXCL-1, CXCL-2, CXCL-3 and interleukin (IL)-8 chemokines. This effect was predominantly mediated by the cytokines of the IL-1 family secreted by the epithelial cells. Thus, prostate epithelial cells induced the secretion of proinflammatory and cancer-promoting chemokines by prostate stromal cells. Such interactions might contribute to prostatic inflammation and progression at early stages of prostate cancer formation.


Development | 2011

p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes.

Ariel Rinon; Alina Molchadsky; Elisha Nathan; Gili Yovel; Varda Rotter; Rachel Sarig; Eldad Tzahor

Neural crest development involves epithelial-mesenchymal transition (EMT), during which epithelial cells are converted into individual migratory cells. Notably, the same signaling pathways regulate EMT function during both development and tumor metastasis. p53 plays multiple roles in the prevention of tumor development; however, its precise roles during embryogenesis are less clear. We have investigated the role of p53 in early cranial neural crest (CNC) development in chick and mouse embryos. In the mouse, p53 knockout embryos displayed broad craniofacial defects in skeletal, neuronal and muscle tissues. In the chick, p53 is expressed in CNC progenitors and its expression decreases with their delamination from the neural tube. Stabilization of p53 protein using a pharmacological inhibitor of its negative regulator, MDM2, resulted in reduced SNAIL2 (SLUG) and ETS1 expression, fewer migrating CNC cells and in craniofacial defects. By contrast, electroporation of a dominant-negative p53 construct increased PAX7+ SOX9+ CNC progenitors and EMT/delamination of CNC from the neural tube, although the migration of these cells to the periphery was impaired. Investigating the underlying molecular mechanisms revealed that p53 coordinates CNC cell growth and EMT/delamination processes by affecting cell cycle gene expression and proliferation at discrete developmental stages; disruption of these processes can lead to craniofacial defects.


Carcinogenesis | 2014

The paradigm of mutant p53-expressing cancer stem cells and drug resistance.

Yoav Shetzer; Hilla Solomon; Gabriela Koifman; Alina Molchadsky; Stav Horesh; Varda Rotter

It is well accepted that expression of mutant p53 involves the gain of oncogenic-specific activities accentuating the malignant phenotype. Depending on the specific cancer type, mutant p53 can contribute to either the early or the late events of the multiphase process underlying the transformation of a normal cell into a cancerous one. This multifactorial system is evident in ~50% of human cancers. Mutant p53 was shown to interfere with a variety of cellular functions that lead to augmented cell survival, cellular plasticity, aberration of DNA repair machinery and other effects. All these effects culminate in the acquisition of drug resistance often seen in cancer cells. Interestingly, drug resistance has also been suggested to be associated with cancer stem cells (CSCs), which reside within growing tumors. The notion that p53 plays a regulatory role in the life of stem cells, coupled with the observations that p53 mutations may contribute to the evolvement of CSCs makes it challenging to speculate that drug resistance and cancer recurrence are mediated by CSCs expressing mutant p53.


Cell Death & Differentiation | 2013

p53 Counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition

Ran Brosh; Y Assia-Alroy; Alina Molchadsky; Chamutal Bornstein; Elya Dekel; Shalom Madar; Yoav Shetzer; Noa Rivlin; Naomi Goldfinger; Rachel Sarig; Varda Rotter

The process of somatic cell reprogramming is gaining increasing interest as reprogrammed cells are considered to hold a great therapeutic potential. However, with current technologies this process is relatively inefficient. Recent studies reported that inhibition of the p53 tumor suppressor profoundly facilitates reprogramming and attributed this effect to the ability of p53 to restrict proliferation and induce apoptosis. Given that mesenchymal-to-epithelial transition (MET) was recently shown to be necessary for reprogramming of fibroblasts, we investigated whether p53 counteracts reprogramming by affecting MET. We found that p53 restricts MET during the early phases of reprogramming and that this effect is primarily mediated by the ability of p53 to inhibit Klf4-dependent activation of epithelial genes. Moreover, transcriptome analysis revealed a large transcriptional signature enriched with epithelial genes, which is markedly induced by Klf4 exclusively in p53−/− cells. We also found that the expression of the epithelial marker E-Cadherin negatively correlates with p53 activity in a variety of mesenchymal cells even before the expression of reprogramming factors. Finally, we demonstrate that the inhibitory effect of p53 on MET is mediated by p21. We conclude that inhibition of the p53–p21 axis predisposes mesenchymal cells to the acquisition of epithelial characteristics and renders them more prone to reprogramming. Our study uncovers a novel mechanism by which p53 restrains reprogramming and highlights the role of p53 in regulating cell plasticity.


Proceedings of the National Academy of Sciences of the United States of America | 2014

Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation

Noa Rivlin; Shir Katz; Maayan Doody; Michal Sheffer; Stav Horesh; Alina Molchadsky; Gabriela Koifman; Yoav Shetzer; Naomi Goldfinger; Varda Rotter; Tamar Geiger

Significance Mutations in p53 lead to cell transformation through the elimination of the WT tumor suppressor activities and the gain of oncogenic ones. In contrast, mouse embryos develop normally, despite the expression of mutant p53. Here, we report that, in ES cells, mutant p53 conformation is shifted to a WT form, leading to transcriptionally active p53 and increased genomic integrity of these cells. Using MS-based proteomics, we were able to isolate a network of interacting proteins that bind mutant p53 and stabilize it to the WT form. These results can serve as a potential platform for p53-based cancer therapy development in the future. p53 is a well-known tumor suppressor that is mutated in over 50% of human cancers. These mutations were shown to exhibit gain of oncogenic function compared with the deletion of the gene. Additionally, p53 has fundamental roles in differentiation and development; nevertheless, mutant p53 mice are viable and develop malignant tumors only on adulthood. We set out to reveal the mechanisms by which embryos are protected from mutant p53–induced transformation using ES cells (ESCs) that express a conformational mutant of p53. We found that, despite harboring mutant p53, the ESCs remain pluripotent and benign and have relatively normal karyotype compared with ESCs knocked out for p53. Additionally, using high-content RNA sequencing, we show that p53 is transcriptionally active in response to DNA damage in mutant ESCs and elevates p53 target genes, such as p21 and btg2. We also show that the conformation of mutant p53 protein in ESCs is stabilized to a WT conformation. Through MS-based interactome analyses, we identified a network of proteins, including the CCT complex, USP7, Aurora kinase, Nedd4, and Trim24, that bind mutant p53 and may shift its conformation to a WT form. We propose this conformational shift as a novel mechanism of maintenance of genomic integrity, despite p53 mutation. Harnessing the ability of these protein interactors to transform the oncogenic mutant p53 to the tumor suppressor WT form can be the basis for future development of p53-targeted cancer therapy.

Collaboration


Dive into the Alina Molchadsky's collaboration.

Top Co-Authors

Avatar

Varda Rotter

Weizmann Institute of Science

View shared research outputs
Top Co-Authors

Avatar

Naomi Goldfinger

Weizmann Institute of Science

View shared research outputs
Top Co-Authors

Avatar

Rachel Sarig

Weizmann Institute of Science

View shared research outputs
Top Co-Authors

Avatar

Noa Rivlin

Weizmann Institute of Science

View shared research outputs
Top Co-Authors

Avatar

Yoav Shetzer

Weizmann Institute of Science

View shared research outputs
Top Co-Authors

Avatar

Ran Brosh

Weizmann Institute of Science

View shared research outputs
Top Co-Authors

Avatar

Hilla Solomon

Weizmann Institute of Science

View shared research outputs
Top Co-Authors

Avatar

Ira Kogan-Sakin

Weizmann Institute of Science

View shared research outputs
Top Co-Authors

Avatar

Shalom Madar

Weizmann Institute of Science

View shared research outputs
Top Co-Authors

Avatar

Gabriela Koifman

Weizmann Institute of Science

View shared research outputs
Researchain Logo
Decentralizing Knowledge